But two previous cases of such post-treatment control in children have been reported:

The "Mississippi Baby" was born with HIV in 2010, received anti-HIV treatment beginning 30 hours after birth, stopped therapy around 18 months of age, and controlled the virus without drugs for 27 months before it reappeared in her blood.

In 2015, investigators reported the case of a French child who was born with HIV in 1996, started therapy at age 3 months, and stopped sometime between ages 5.5 and 7 years. She continues to control the virus without drugs more than 11 years later.

But most HIV-positive people, whether children or adults, see their virus rebound within a few weeks or at most months.

Tim Henrich, MD, of the University of California San Francisco, reported here on an adult patient first treated in the "hyperacute" phase -- within about 10 days of infection. After some 2 years of treatment, during which HIV was not detectable even using ultra-sensitive tests, the patient stopped therapy.

Unusually, the patient remained in remission for 224 days, or more than 7 months, Henrich reported. But then the HIV returned with a vengeance -- from plasma HIV RNA of 36 copies per mL to more than 56,000 copies within 6 days.

In other words, "there's a broad spectrum from when you stop therapy to when you rebound," commented Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), which was one of the sponsors of the study in which the South African child is enrolled.

"The exciting thing is: what is it that makes that difference?," he told reporters. "Is it an immunological response? Is it something about the virus? Is there immune activation in one individual that you don't see in another individual?"

He added that early treatment "seems to be a very important common denominator" because it reserves immune function and reduces the number of cells latently infected with HIV the reservoir that is responsible for rebound when treatment is stopped.

On the other hand, even a very small reservoir is not enough, Henrich noted: His group calculated that their patient had at most 200 such cells, but eventually one of them activated and began producing HIV again.

The South African child, whose case was reported here, was diagnosed with HIV infection in 2007 when she was 32 days old. She was enrolled in the Children with HIV Early Antiretroviral Therapy (CHER) clinical trial.

The infants in the trial were randomly assigned to get antiretroviral for 40 or 96 weeks, or to have their treatment deferred until their immune systems began to fail. The child in the current study was one of 143 assigned to get 40 weeks of treatment.

Before treatment, the child had a plasma viral load of more than 750,000 copies of HIV RNA per mL, but the therapy quickly suppressed that to undetectable levels. According to the study plan, the researchers stopped treatment after 40 weeks and have closely followed the child's health since.

Recent analysis of stored blood samples show that the child has maintained an undetectable level of HIV, Violari reported.

Lab and clinical studies have shown a small reservoir of virus but no other evidence of HIV infection. She has weak antibody and CD4-positive T cell responses to HIV and no detectable CD8-positive T cells responses. Also, her level of immune activation was low and similar to what is seen in HIV-negative people.

The case is "technically an outlier," Fauci said, although it's one that might hold important clues about HIV. But a current NIH clinical trial called IMPAACT P1115 might yield more clues: It is testing the idea that treating HIV-infected babies within 2 days of birth might allow long-term remission after treatment is stopped.

The study has now enrolled nearly 400 HIV-exposed infants, 42 with HIV, and the first children may become eligible to stop therapy later this year.

The study by Violari's group was supported by NIAID, the Medical Research Council Clinical Trials Unit at University College London, the Departments of Health of the Western Cape and Gauteng in South Africa, and ViiV Healthcare, the EPIICAL Consortium. and the National Research Foundation of South Africa. Violari disclosed no relevant relationships with industry.

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.